SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on October 6, 2010, reporting an event that occurred on October 1, 2010. The company is a biopharmaceutical entity based in Castle Rock, Colorado, focused on the development of diagnostic tests, specifically the AppyScore blood-based appendicitis test.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the receipt of a federal securities class action lawsuit. The complaint, captioned John Wolfe v. AspenBio Pharma, Inc. et al. (Case No. CV10 7365), was filed in the United States District Court for the Central District of California. The suit covers the period from February 22, 2007, to July 19, 2010, and alleges violations of Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934 regarding the AppyScore product.
Outlook, Risks, and Management Commentary
Management states that the Company and the individual defendants (certain officers and directors) are evaluating the complaint. They believe the allegations are without merit and intend to vigorously defend against the claims. The filing identifies the litigation as a significant contingency and risk to the company.
Key Facts for Investor Verification
- Litigation Status: Verify the current status of Case No. CV10 7365 and any subsequent rulings or settlements.
- Defendants: Confirm which specific officers and directors are named in the complaint.
- Financial Impact: Assess potential legal costs and the impact of the lawsuit on the company's capitalization and stock price.
- Product Development: Review the development status and regulatory standing of the AppyScore test, which is the subject of the allegations.